|
1
|
Scully RE: World Health Organization
classification and nomenclature of ovarian cancer. J Natl Cancer
Inst Monogr. 42:5–7. 1975.PubMed/NCBI
|
|
2
|
McGuire V, Jesser CA and Whittemore AS:
Survival among U.S. women with invasive epithelial ovarian cancer.
Gynecol Oncol. 84:399–403. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kennedy AW, Biscotti CV, Hart WR and
Webster KD: Ovarian clear cell adenocarcinoma. Gynecol Oncol.
32:342–349. 1989. View Article : Google Scholar
|
|
4
|
Sugiyama T, Kamura T, Kigawa J, et al:
Clinical characteristics of clear cell carcinoma of the ovary: a
distinct histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakayama K, Nakayama N, Kurman RJ, et al:
Sequence mutations and amplification of PIK3CA and AKT2 genes in
purified ovarian serous neoplasms. Cancer Biol Ther. 5:779–785.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang L, Huang J, Yang N, et al:
Integrative genomic analysis of phosphatidylinositol 3′-kinase
family identifies PIK3R3 as a potential therapeutic target
in epithelial ovarian cancer. Clin Cancer Res. 13:5314–5321.
2007.
|
|
8
|
Campbell IG, Russell SE, Choong DYH, et
al: Mutation of the PIK3CA gene in ovarian and breast
cancer. Clin Cancer Res. 64:7678–7681. 2004.
|
|
9
|
Altomare DA, Wang HQ, Skele KL, et al: AKT
and mTOR phosphorylation is frequently detected in ovarian cancer
and can be targeted to disrupt ovarian tumor cell growth. Oncogene.
23:5853–5857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mabuchi S, Kawase C, Altomare DA, et al:
mTOR is a promising therapeutic target both in cisplatin-sensitive
and cisplatin-resistant clear cell carcinoma of the ovary. Clin
Cancer Res. 15:5404–5413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuo KT, Mao TL, Jones S, et al: Frequent
activating mutations of PIK3CA in ovarian clear cell
carcinoma. Am J Pathol. 174:1597–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maira SM, Stauffer F, Brueggen J, et al:
Identification and characterization of NVP-BEZ235, a new orally
available dual phosphatidylinositol 3-kinase/mammalian target of
rapamycin inhibitor with potent in vivo antitumor activity.
Mol Cancer Ther. 7:1851–1863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brachmann S, Hofmann I, Schnell C, et al:
Specific apoptosis induction by the dual PI3K/mTOR inhibitor
NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.
Proc Natl Acad Sci. 106:22299–22304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho DC, Cohen MB, Panka DJ, et al: The
efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235
compared with rapamycin in renal cell carcinoma. Clin Cancer Res.
16:3628–3638. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Itamochi H, Kato M, Nishimura M, et al:
Establishment and characterization of a novel ovarian serous
adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and
HER2. Hum Cell. 25:111–115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Itamochi H, Kato M, Nishimura M, et al:
Establishment and characterization of a novel ovarian clear cell
carcinoma cell line, TU-OC-1, with a mutation in the PIK3CA
gene. Hum Cell. 26:121–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Itamochi H, Oishi T, Shimada M, et al:
Inhibiting the mTOR pathway synergistically enhances cytotoxicity
in ovarian cancer cells induced by etoposide through upregulation
of c-Jun. Clin Cancer Res. 17:4742–4750. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McIntyre AJ, Summersgill BM, Spendlove HE,
et al: Activating mutations and/or expression levels of tyrosine
kinase receptors GRB7, RAS, and BRAF in
testicular germ cell tumors. Neoplasia. 7:1047–1052. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li VSW, Wong CW, Chan TL, et al: Mutations
of PIK3CA in gastric adenocarcinoma. BMC Cancer. 5:292005.
View Article : Google Scholar
|
|
20
|
Rauh-Hein AJ, Winograd D, Growdon WB, et
al: Prognostic determinants in patients with uterine and ovarian
clear carcinoma. Gynecol Oncol. 125:376–380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pectasides D, Fountzilas G, Aravantinos G,
et al: Advanced stage clear-cell epithelial ovarian cancer: the
Hellenic Cooperative Oncology Group experience. Gynecol Oncol.
102:285–291. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyazawa M, Yasuda M, Fujita M, et al:
Therapeutic strategy targeting the mTOR-HIF-1α-VEGF pathway in
ovarian clear cell adenocarcinoma. Pathol Int. 59:19–27. 2009.
|
|
23
|
Itamochi H and Kigawa J: Clinical trials
and future potential of targeted therapy for ovarian cancer. Int J
Clin Oncol. 17:430–440. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Efeyan A and Sabatini DM: mTOR and cancer:
many loops in one pathway. Curr Opin Cell Biol. 22:169–176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harrington LS, Findlay GM, Gray A, et al:
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via
regulation of IRS proteins. J Cell Biol. 166:213–223. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hartley D and Cooper GM: Role of mTOR in
the degradation of IRS-1: regulation of PP2A activity. J Cell
Biochem. 85:304–314. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shoji K, Oda K, Kashiyama T, et al:
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor,
NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial
carcinomas. PLoS One. 7:e374312012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Montero JC, Chen X, Ocaria A, et al:
Predominance of mTORC1 over mTORC2 in the regulation of
proliferation of ovarian cancer cells: therapeutic implications.
Mol Cancer Ther. 11:1342–1352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Santiskulvong C, Konecny GE, Fekete M, et
al: Dual targeting of phosphoinositide 3-kinase and mammalian
target of rapamycin using NVP-BEZ235 as a novel therapeutic
approach in human ovarian carcinoma. Clin Cancer Res. 17:2373–2384.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rahman M, Nakayama K, Rahman MT, et al:
Clinicopathologic and biological analysis of PIK3CA mutation
in ovarian clear cell carcinoma. Hum Pathol. 43:2197–2206.
2012.PubMed/NCBI
|
